BiotechTube
Home/Sulfateq/Kees van der Graaf
KV

Kees van der Graaf

Chief Executive Officer

Sulfateq

Therapeutic Areas

NeurodegenerationChronic Kidney DiseaseCardiovascular DiseasePulmonary Disease

Sulfateq Pipeline

DrugIndicationPhase
SUL-238Parkinson's Disease (Mitochondrial Dysfunction)Phase 2
SUL-150Diabetic Kidney Disease, COPD, Heart Failure, NeurodegenerationPreclinical
SUL-151Diabetic Kidney Disease, COPD, Heart Failure, NeurodegenerationPreclinical

Leadership Team at Sulfateq

DS
Daniël Swart
Chief Operating Officer
GK
Guido Krenning
Chief Scientific Officer
HB
Hans Bruining
Chief Financial Officer
RH
Rob Henning
Chair, Scientific Advisory Board
View full Sulfateq profile